Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva flogs animal health business to Bayer for $145m

This article was originally published in Scrip

Executive Summary

Teva has sold its US-based animal health business to Bayer for $145 million in line with its strategy to focus solely on its core human health business. Itzhak Krinsky, Teva’s group executive vice-president and head of business development, said, “As part of our overall strategy to refine our global footprint, we will continue to leverage our product portfolio and R&D efforts while selling or out-licensing assets that no longer fit within the scope of our business." The deal includes $60 million upfront and $85 million in manufacturing and sales milestones, and is expected to close in 2013. Bayer will integrate the assets into its companion and food animal products line.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts